Preliminary Results of a Phase 1 Study of Flotetuzumab, a CD123 x CD3 Bispecific Dart® Protein, in Patients with Relapsed/Refractory Acute Myeloid Leukemia and Myelodysplastic Syndrome
Geoffrey L. Uy(Memorial Sloan Kettering Cancer Center), John F. DiPersio(Washington University in St. Louis), Ezio Bonvini(MacroGenics (United States)), Daner Li(MacroGenics (United States)), Matteo Giovanni Carrabba(Vita-Salute San Raffaele University), Martha Arellano(Memorial Sloan Kettering Cancer Center), Michele Shannon(MacroGenics (United States)), Fabio Ciceri(Vita-Salute San Raffaele University), Matthew C. Foster(University of North Carolina at Chapel Hill), Gerwin Huls(University Medical Center Groningen), Jan Baughman(University of California System), Bob Löwenberg(Unknown), Jon M. Wigginton(Bristol-Myers Squibb (United States)), Norbert Vey(Centre de Recherche en Cancérologie de Marseille), John E. Godwin(Providence Portland Medical Center), Carmen Ballesteros‐Merino(Cancer Institute (WIA)), Michael P. Rettig, David A. Rizzieri(Duke University), Carlo Bifulco(Providence Health & Services), Bernard A. Fox(Oregon Health & Science University), Ross La Motte‐Mohs(MacroGenics (United States)), Kathy Tran(McGovern Institute for Brain Research), Giovanni Martinelli(University of Bologna), Kenneth Jacobs(MacroGenics (United States)), Nadia Lonsdale(MacroGenics (United States)), Karen Spohn(MacroGenics (United States)), Max S. Topp(Universitätsklinikum Würzburg), Jichao Sun(MacroGenics (United States)), Stefania Paolini(IRCCS Azienda Ospedliero-Universitaria di Bologna Policlinico di Sant'Orsola), Hélène Lelièvre(Domain Therapeutics (France)), Jan Davidson‐Moncada(MacroGenics (United States))
Cited by 62
Related Papers
Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer
|New England Journal of Medicine|2012|12.6k
Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer
|New England Journal of Medicine|2012|8k
Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel
|Blood|2016|5.9k
Nivolumab plus Ipilimumab in Advanced Melanoma
|New England Journal of Medicine|2013|4.2k
ASTCT Consensus Grading for Cytokine Release Syndrome and Neurologic Toxicity Associated with Immune Effector Cells
|Transplantation and Cellular Therapy|2018|3.6k